ChristosEmmanouelEmmanouilidesMD

Oncology • Los Angeles, CA

Co-Director, Bone Marrow/Stem Cell Transplantation; Bone Marrow / Stem Cell Transplantation Program; Associate Professor, Medicine; Member, JCCC Clinical/Translational, UCLA School of Medicine

Join to view full profile

Dr. Emmanouilides is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Emmanouilides' full profile

Already have an account?

Office
200 Medical Plaza
365
Los Angeles, CA 90095
Phone+1 310-825-0631

Education & Training

UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Hematology and Medical Oncology, 1993 - 1995
UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Infectious Disease, 1992 - 1993
University of ConnecticutResidency, Internal Medicine, 1990 - 1992
University of ConnecticutInternship, Internal Medicine, 1989 - 1990
University of AthensClass of 1984

Clinical Trials

Combination Chemotherapy With or Without Amifostine in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Hodgkin's Disease Undergoing Stem Cell Transplantation Start of enrollment: 1997 Nov 01
Completed
Phase 2
Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With B-cell Non-Hodgkin's Lymphoma That Has Relapsed Following Peripheral Stem Cell Transplantation Start of enrollment: 1999 May 01
Completed
Phase 2
Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Hematologic Cancer
Withdrawn
Phase 1
Growth Factor to Prevent Oral Mucositis in Patients With Hematologic Cancer Start of enrollment: 2000 Jan 01
Completed
Phase 2
Fludarabine in Treating Patients With Steroid-Resistant Chronic Graft- Versus-Host Disease
Unknown status
Phase 1, Phase 2
Rituximab in Treating Patients With Waldenstrom's Macroglobulinemia Start of enrollment: 1999 Dec 01
Completed
Phase 2
Monoclonal Antibody in Treating Patients With Acute Myelogenous Leukemia Start of enrollment: 2001 Feb 01
Unknown status
Phase 2
Rituximab Plus Fludarabine in Treating Patients With Waldenstrom's Macroglobulinemia Start of enrollment: 2001 Sep 01
Completed
Phase 2
Biological Therapy Plus Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma Start of enrollment: 2002 Mar 01
Completed
Phase 1
Epratuzumab in Treating Patients With Non-Hodgkin's Lymphoma Start of enrollment: 2002 May 01
Unknown status
Phase 2
Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Waldenstrom's Macroglobulinemia Start of enrollment: 2003 Apr 01
Terminated
Phase 1
Gemcitabine, Cisplatin, and Dexamethasone in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma Start of enrollment: 2003 Jun 01
Completed
Phase 2
Paclitaxel and Carboplatin Combination as 1st Line Treatment in Ovarian Carcinomas Start of enrollment: 2008 Jan 01
Completed
Phase 1, Phase 2
Metronomic Vinorelbine and Bevacizumab in Patients With Non Small Cell Lung Cancer Start of enrollment: 2008 Nov 01
Completed
Phase 2
Docetaxel/Carboplatin Versus Docetaxel/Caelyx in Pretreated Patients With Ovarian Carcinoma Start of enrollment: 2005 Oct 01
Terminated
Phase 2
Join now to see all

Publications & Presentations

PubMed

4 citations
Prognostic Role of Circulating Tumor Cells in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Cabazitaxel: A Prospective Biomarker Study.
Filippos Koinis, Zafeiris Zafeiriou, Ippokratis Messaritakis, Panagiotis Katsaounis, Anna Koumarianou
Cancers. 2023-09-11
Front-Line Bevacizumab plus Chemotherapy with or without Maintenance Therapy for Metastatic Breast Cancer: An Observational Study by the Hellenic Oncology Research Group.
Stefania Kokkali, Emmanouil Saloustros, Dimitra Stefanou, Paris Makrantonakis, Nikolaos Kentepozidis
Current Oncology. 2022-02-17
4 citations
Update on the association of hepatitis B with intrahepatic cholangiocarcinoma: Is there new evidence?
Nikolaos Fragkou, Lazaros Sideras, Panteleimon Panas, Christos Emmanouilides, Emmanouil Sinakos
World Journal of Gastroenterology. 2021-07-21